About the Study : For patients with breast cancer receiving injectable gonadotropin-releasing hormone agonist therapy, a home injection model supported by telemedicine reduced treatment burden by improving convenience and saving time for many participants. Most patients who completed home injections chose to continue this approach beyond the pilot. Barriers such as insurance denials and higher copayments for at-home administration may limit broader implementation.
Explore JAMA+ Women's Health for more Women's Health research, commentary, multimedia, and resources from across JAMA Network.
Led by Editor in Chief Linda Brubaker, MD, JAMA+ Women's Health is a curated source of trusted clinical information that advances health care for women worldwide. Dr Brubaker is also a JAMA Deputy Editor.
Corresponding Author : Erin M. Bange, MD, MSCE, Department of Medicine, Memorial Sloan Kettering Cancer Center Sidney Kimmel Center for Prostate and Urologic Cancers, 353 E 68th St, New York, NY 10065 ( bangee@mskcc.org ).
10.1001/jamanetworkopen.2026.29406
To access the embargoed study: Visit our JAMA Network Media Center at this link https://media.jamanetwork.com/
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Editor's Note : Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
JAMA Network Open